September 2004

Inobrodib is being developed as a first-in-class oral cancer drug that the company says will be able to treat not only multiple myeloma, but other specific cancers as well.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

The LP.8.1 variant of the SARS-CoV-2 virus differs from the JN.1 family that previous vaccines had been designed to target, and has surpassed JN.1 as the variant circulating most widely worldwide.

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

Merck will have early-stage opportunities to help startups set up for future success in the pharmaceutical and life sciences fields.

Six winners and two honorable mentions were revealed at ISPE’s Europe Annual Conference in London.